JP2005525391A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525391A5
JP2005525391A5 JP2003579835A JP2003579835A JP2005525391A5 JP 2005525391 A5 JP2005525391 A5 JP 2005525391A5 JP 2003579835 A JP2003579835 A JP 2003579835A JP 2003579835 A JP2003579835 A JP 2003579835A JP 2005525391 A5 JP2005525391 A5 JP 2005525391A5
Authority
JP
Japan
Prior art keywords
statin
galantamine
amount
active ingredient
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003324 external-priority patent/WO2003082298A1/en
Publication of JP2005525391A publication Critical patent/JP2005525391A/ja
Publication of JP2005525391A5 publication Critical patent/JP2005525391A5/ja
Pending legal-status Critical Current

Links

JP2003579835A 2002-04-02 2003-03-28 認識維持の強化のためのスタチン治療 Pending JP2005525391A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (2)

Publication Number Publication Date
JP2005525391A JP2005525391A (ja) 2005-08-25
JP2005525391A5 true JP2005525391A5 (https=) 2006-01-26

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579835A Pending JP2005525391A (ja) 2002-04-02 2003-03-28 認識維持の強化のためのスタチン治療

Country Status (21)

Country Link
EP (1) EP1492539B1 (https=)
JP (1) JP2005525391A (https=)
KR (1) KR100986194B1 (https=)
CN (1) CN100528164C (https=)
AT (1) ATE331523T1 (https=)
AU (1) AU2003226753B2 (https=)
BR (1) BR0308293A (https=)
CA (1) CA2480275C (https=)
CY (1) CY1105545T1 (https=)
DE (1) DE60306503T2 (https=)
DK (1) DK1492539T3 (https=)
EA (1) EA013069B1 (https=)
ES (1) ES2268393T3 (https=)
IL (2) IL164317A0 (https=)
MX (1) MXPA04009535A (https=)
NO (1) NO20044698L (https=)
NZ (1) NZ536111A (https=)
PL (1) PL211160B1 (https=)
PT (1) PT1492539E (https=)
UA (1) UA79605C2 (https=)
WO (1) WO2003082298A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
WO2005123068A2 (en) * 2004-06-08 2005-12-29 Axonyx, Inc. Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2015089349A1 (en) * 2013-12-13 2015-06-18 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Similar Documents

Publication Publication Date Title
RU96112139A (ru) Фармацевтический препарат для перорального приема
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
HK19395A (en) Film-coated solid dosage form of anti-migraine drug
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
JP2004502731A (ja) スタチン、エストロゲン剤および所望によるエストロゲンの組み合わせ
RU2003100507A (ru) Фармацевтические композиции
CN101795684A (zh) 他汀类化合物与抗肥胖药的组合
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
IL310115A (en) Treatment of his hyporesponders
JP2005525391A5 (https=)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
RU2004131213A (ru) Лекарственные формы трамадола замедленного высвобождения
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
DE60331920D1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
WO2005058310A3 (en) Use of stating for the treatment of metabolic syndrome
RU2750934C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ
JP2007534731A5 (https=)
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
CN100430057C (zh) 左旋氨氯地平和阿托伐他汀的药物组合物
RU2003132049A (ru) Фармацевтическая композиция, обладающая церебровазодилатирующей и ноотропной активностью
JPH1081633A (ja) 医薬組成物
RU2001113270A (ru) Лечение, направленное на улучшение познавательной способности
JP2010150288A (ja) スタチン及びガンマーオリザノールを含有する医薬組成物